Antibody therapy
Alemtuzumab
ALPN-101
Antithymocyte globulin
Axatilimab
Basiliximab
Begelomab
Daclizumab
Etanercept
Infliximab
Inolimomab
Itolizumab
Natalizumab
Rituximab
Tocilizumab
Vedolizumab
BCL-2 inhibitors
Venetoclax
Biological therapy
Abatacept
F-652
BTK inhibitors
Ibrutinib
Calcineurin inhibitors
Cyclosporin A
Tacrolimus
Cellular therapy
Allo-BMT
Allo-CBT
Allo-HSCT
Allo-NKT
Auto-HSCT
DLI
Extracorporeal photopheresis
Mesenchymal stromal cells
NEXI-001
Orca-T
Chemokine receptor antagonists
Maraviroc
Chemotherapy
Busulfan
Cyclophosphamide
Fludarabine
Melphalan
Methotrexate
Treosulfan
Endothelial protection
Defibrotide
HDAC inhibitors
Panobinostat
Vorinostat
Hypomethylating agents
Azacitidine
Decitabine
Immune modulators
Interleukin-2
Pomalidomide
Immunosuppressants
Mycophenolate mofetil
JAK inhibitors
Baricitinib
Itacitinib
Ruxolitinib
Microbiota therapy
Fecal microbiota transplant
MaaT013
mTOR inhibitors
Sirolimus
Nuclear receptor agonists
Methylprednisolone
Prednisone
Protease inhibitors
α1-Antitrypsin
Proteasome inhibitors
Bortezomib
Carfilzomib
Ixazomib
ROCK inhibitors
KD025
SYK inhibitors
Entospletinib
Fostamatinib